B. Riley Securities Maintains Neutral on Bicycle Therapeutics, Lowers Price Target to $17
B. Riley Securities Maintains Neutral on Bicycle Therapeutics, Lowers Price Target to $17
b. Riley Securities維持對Bicycle Therapeutics的中立評級,將目標價下調至17美元
B. Riley Securities analyst Kalpit Patel maintains Bicycle Therapeutics (NASDAQ:BCYC) with a Neutral and lowers the price target from $28 to $17.
b. Riley Securities 分析師 Kalpit Patel 維持 Bicycle Therapeutics (納斯達克:BCYC) 的中立評級,並將目標價從28美元下調至17美元。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。